Category: News

QuiremSpheres® Observational Study

On June 7th the first site of the QuiremSpheres® Observational Study, the Universitätsklinikum Carl Gustav Carus in Dresden, Germany, was opened for registration. The observational study aims to further confirm treatment safety and efficacy using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases.

Read More »

First patient at the Istituto Nazionale dei Tumori hospital in Milan, Italy

On May 22th 2018, the first patient at the Istituto Nazionale dei Tumori was treated with QuiremSpheres®. The team, led by Prof. Dr. Mazzaferro (surgeon), Dr. Bhoori (hepatologist), Dr. Maccauro (nuclear medicine), Dr. Carlo Spreafico (Interventional Radiology) and Dr. Chieza (medical physics) used QuiremSpheres® for treatment of a patient suffering from

Read More »

A new milestone in the collaboration between RTM and Quirem Medical

As of the 22nd of May 2018, the Radboud Translational Medicine (RTM) is fully operational for performing the final steps in the manufacturing process of QuiremSpheres®. The RTM offers state-of-the-art facilities for the production and processing of radioactive pharmaceuticals and medical devices. Jan Sigger, CEO of Quirem Medical, comments: “It

Read More »

First patient treated with QuiremSpheres® at the Florence Nightingale hospital in Turkey

On May 4th 2018, the first patient in Turkey was treated with QuiremSpheres® at the Florence Nightingale Hospital in Istanbul. Prof. Dr. Murat Cantaşdemir and Dr. Abdullah Yakupoğlu, both interventional radiologists, together with nuclear physician Prof. Dr. Cüneyt Türkmen, successfully performed the radioembolization procedure with QuiremSpheres® (holmium-based microspheres). The patient

Read More »

Terumo and Quirem Medical welcome the positive reimbursement decision for QuiremSpheres® in the Netherlands

Terumo and Quirem Medical welcome an important milestone for QuiremSpheres® in the Netherlands and in Europe. QuiremSpheres® is now reimbursed for liver-dominant, non-resectable, colorectal liver metastases in the salvage setting[1]. The National Healthcare Institute (‘Zorginstituut’) concludes that radioembolization treatment with holmium-166 microspheres, which has been developed in the Netherlands, meets

Read More »

QuiremSpheres® will be reimbursed in Belgium as of 1 October 2017

We are happy to announce that QuiremSpheres® will be fully reimbursed in Belgium as of 1 October 2017. Jan Sigger, CEO of Quirem Medical B.V., the manufacturer of QuiremSpheres®, said: “The decision of the Belgian authorities to fully reimburse QuiremSpheres® is consistent with the fact that our product uses the

Read More »

QuiremSpheres® is now available in European markets

The European launch of QuiremSpheres® was officially announced at CIRSE 2017 in Copenhagen, Denmark. QuiremSpheres® are now available to clinicians in various markets across Europe. More information can be found on the website of our strategic partner and exclusive global distributor Terumo.

Read More »

First commercial clinical case using QuiremSpheres®

On March 14th 2017 QuiremSpheres® was used for the first time outside a research setting to treat a patient with metastatic colorectal cancer in the liver at the University Clinic Carl Gustav Carus in Dresden, Germany. Click here for more information.

Read More »